Eoe Clinical Trials 2023

Eoe Clinical Trials 2023

Eoe research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in eoe clinical trials today.

Eoe Clinical Trials

Here are the 6 most popular medical studies for eoe

Popular filter options for eoe trials

Phase 3 Eoe Clinical Trials

View 28 phase 3 eoe medical studies.

Eoe Clinical Trials With No Placebo

View 28 eoe medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to eoe

What are the top hospitals conducting eoe research?

When it comes to advancing the understanding and treatment of eosinophilic esophagitis (EOE), several top hospitals are leading the way in clinical trials. In Cincinnati, the Cincinnati Children's Hospital Medical Center takes center stage with four active EOE trials and a remarkable 21 completed trials dedicated to this condition. Since conducting their first trial in 2001, this hospital has been at the forefront of research into EOE, a chronic allergic inflammatory disease that affects the esophagus.

Meanwhile, in Philadelphia, two renowned institutions are making significant contributions as well. The University of Pennsylvania is currently involved in three active EOE trials while having an impressive history of 18 completed studies since their inaugural trial in 2011. At the Children's Hospital of Philadelphia, researchers are also conducting three ongoing clinical trials for EOE while having conducted twelve previous studies since initiating their first trial in 2007.

In Los Angeles, Gastrointestinal Biosciences enters the scene as a key player with three active EOE trials. Although they might have fewer completed studies compared to other institutions due to being relatively new on the scene (their first recorded trial was just recently conducted in 2021), their dedication signifies promising progress towards understanding and combating this complex condition.

Lastly but not least important is Nature Coast Clinical Research LLC based in Inverness which contributes significantly by actively participating over time through three concurrent eoe investigations building upon six successfully accomplished projects from starting its pioneering investigations back from year2015

These esteemed hospitals and research centers across different locations demonstrate a shared commitment to unraveling the mysteries behind EOE - an illness that often goes unrecognized or misdiagnosed but can lead to severe complications if left untreated. Through these collaborative efforts involving cutting-edge clinical trials and years-long research endeavors – we inch closer every day toward better treatments and improved quality of life for individuals living with eosinophilic esophagitis

Which are the best cities for eoe clinical trials?

When it comes to eoe clinical trials, several cities have emerged as key hubs for research and development. Philadelphia, Pennsylvania leads the pack with 15 active trials exploring treatments like CC-93538, Dupilumab, and Barzolvolimab (CDX-0159). Cincinnati, Ohio follows closely behind with 12 ongoing studies focused on similar interventions such as CC-93538 and Dupilumab. Lastly, Boston, Massachusetts boasts 11 active trials examining options like CC-93538 and Barzolvolimab (CDX-0159), while Salt Lake City, Utah and Iowa City, Iowa also contribute to the advancement of eoe treatment through their respective clinical trials. These cities offer individuals dealing with eosinophilic esophagitis access to cutting-edge research that may lead to improved care options in the future.

Which are the top treatments for eoe being explored in clinical trials?

Exploratory clinical trials are paving the way for promising treatments in the management of eosinophilic esophagitis (EoE). One standout contender is Dupilumab, currently being tested in three active trials. Since its initial listing in 2015, it has amassed a total of four EoE trials, demonstrating its potential as a therapeutic option. Another noteworthy treatment under investigation is CC-93538, with two ongoing clinical trials and a total of three EoE trials since its recent introduction in 2021. These innovative therapies hold great promise for improving outcomes and quality of life for individuals living with EoE.

What are the most recent clinical trials for eoe?

Exciting progress is being made in the field of eosinophilic esophagitis (EOE) with recent clinical trials shedding light on potential treatment options. One notable trial involves an active drug specifically developed for EOE, which has entered Phase 2 and offers promise for patients. Additionally, Barzolvolimab (CDX-0159), another Phase 2 trial medication, shows encouraging results in its potential to address EOE symptoms effectively. With ongoing studies like Part A: Phase 2 for EOE and EP-104IAR 4 mg showcasing promising outcomes in their respective phases, there is growing hope that improved therapeutic approaches will emerge to alleviate the burden faced by individuals with this condition.

What eoe clinical trials were recently completed?

Several noteworthy clinical trials for eosinophilic esophagitis (EoE) have recently concluded, highlighting progress in the search for effective treatments. In October 2021, Revolo Biotherapeutics completed a trial investigating IRL201104 as a potential therapy. Last September, Ellodi Pharmaceuticals wrapped up their study on APT-1011. Additionally, Allakos, Inc. had two trials reach completion: one testing AK002 in May 2021 and another in November 2018. Other completed trials include Arena Pharmaceuticals' Etrasimod in December 2020; lirentelimab by Allakos, Inc., also in December 2020; Mepolizumab 300 mg conducted by the University of North carolina at Chapel Hill in March 2019; Dupilumab sponsored by Regeneron Pharmaceuticals in September 2018; and Benralizumab led by Children's Hospital Medical Center Cincinnati in April 2018. These studies signify significant research efforts to advance our understanding and treatment options for EoE patients.